Twist Bioscience Corporation (NASDAQ:TWST) Shares Sold by Teacher Retirement System of Texas

Teacher Retirement System of Texas decreased its stake in Twist Bioscience Corporation (NASDAQ:TWST) by 7.7% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 16,027 shares of the company’s stock after selling 1,330 shares during the quarter. Teacher Retirement System of Texas’ holdings in Twist Bioscience were worth $629,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the stock. Versant Capital Management Inc grew its holdings in shares of Twist Bioscience by 547.2% during the first quarter. Versant Capital Management Inc now owns 686 shares of the company’s stock worth $27,000 after buying an additional 580 shares in the last quarter. GAMMA Investing LLC boosted its position in Twist Bioscience by 68.1% during the first quarter. GAMMA Investing LLC now owns 748 shares of the company’s stock worth $29,000 after acquiring an additional 303 shares during the last quarter. Banque Transatlantique SA purchased a new stake in Twist Bioscience during the 4th quarter valued at about $43,000. GF Fund Management CO. LTD. purchased a new stake in Twist Bioscience during the 4th quarter valued at about $58,000. Finally, US Bancorp DE raised its holdings in Twist Bioscience by 72.0% in the 4th quarter. US Bancorp DE now owns 1,436 shares of the company’s stock valued at $67,000 after acquiring an additional 601 shares during the last quarter.

Wall Street Analysts Forecast Growth

TWST has been the subject of several recent research reports. Guggenheim reaffirmed a “buy” rating and issued a $50.00 price target on shares of Twist Bioscience in a report on Tuesday, May 6th. JPMorgan Chase & Co. cut their target price on Twist Bioscience from $40.00 to $33.00 and set an “underweight” rating for the company in a research note on Tuesday, May 6th. Barclays lowered their price target on shares of Twist Bioscience from $58.00 to $45.00 and set an “overweight” rating on the stock in a research report on Thursday, April 10th. Robert W. Baird dropped their price objective on shares of Twist Bioscience from $54.00 to $44.00 and set an “outperform” rating for the company in a report on Tuesday, May 6th. Finally, The Goldman Sachs Group reduced their target price on shares of Twist Bioscience from $55.00 to $48.00 and set a “buy” rating on the stock in a research note on Tuesday, May 6th. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, Twist Bioscience has an average rating of “Moderate Buy” and an average target price of $50.40.

Twist Bioscience Stock Down 3.8%

TWST opened at $36.37 on Wednesday. Twist Bioscience Corporation has a one year low of $27.12 and a one year high of $60.90. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.24 and a current ratio of 4.51. The stock has a market capitalization of $2.18 billion, a P/E ratio of -11.19 and a beta of 2.41. The business’s 50-day simple moving average is $33.47 and its 200-day simple moving average is $39.68.

Twist Bioscience (NASDAQ:TWST) last announced its earnings results on Monday, May 5th. The company reported ($0.66) EPS for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.10). The business had revenue of $92.79 million during the quarter, compared to analyst estimates of $92.00 million. Twist Bioscience had a negative net margin of 54.98% and a negative return on equity of 33.48%. Analysts anticipate that Twist Bioscience Corporation will post -2.12 EPS for the current year.

Insider Buying and Selling at Twist Bioscience

In other news, insider Dennis Cho sold 689 shares of the company’s stock in a transaction that occurred on Monday, May 5th. The stock was sold at an average price of $37.65, for a total transaction of $25,940.85. Following the completion of the sale, the insider owned 110,849 shares in the company, valued at $4,173,464.85. This represents a 0.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Adam Laponis sold 2,449 shares of the stock in a transaction on Wednesday, July 9th. The stock was sold at an average price of $38.15, for a total value of $93,429.35. Following the sale, the chief financial officer directly owned 103,569 shares of the company’s stock, valued at approximately $3,951,157.35. This represents a 2.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 24,961 shares of company stock valued at $877,006. Corporate insiders own 3.01% of the company’s stock.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.